Form 4: Pulse Biosciences Executive Receives Stock Grant

Pulse Biosciences, Inc. reports a grant of 100,000 Restricted Stock Units to Chief Technology Officer Darrin Uecker.

Summary

• Darrin Uecker, Chief Technology Officer and Director at Pulse Biosciences, Inc., was granted 100,000 Restricted Stock Units (RSUs) on March 23, 2026.
• These RSUs represent a contingent right to receive one share of the company's common stock.
• The RSUs are scheduled to fully vest on March 23, 2029, contingent upon Uecker's continued service with the company until that date.
• Following the grant, Uecker beneficially owns 100,000 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it solely reports a routine equity grant to an executive and does not contain operational or financial performance information.

Positives

• Grant of equity to a key executive (Chief Technology Officer) can signal confidence in future performance and retention of talent.
• The RSU grant is a standard form of long-term incentive compensation, aligning executive interests with shareholder value.
• The vesting schedule over three years encourages long-term commitment from the executive.

Negatives

• The filing does not contain any negative financial or operational information; it solely reports a stock grant.
• The value of the stock grant is not explicitly stated in monetary terms, only the number of units.

Risks

• The vesting of the RSUs is contingent on continued service, meaning any departure before March 23, 2029, would result in forfeiture.
• The value of the RSUs is subject to the future performance and stock price of Pulse Biosciences, Inc.

Future Outlook

The future outlook is not directly addressed in this filing, which is a statement of changes in beneficial ownership. The vesting of the RSUs on March 23, 2029, is a future event tied to continued employment.

Industry Context

StockSavvy.ai notes that grants of Restricted Stock Units to key executives are a common practice in the biotechnology and technology sectors to attract, retain, and incentivize talent, aligning their interests with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The grant itself does not immediately impact share count or value but represents future dilution upon vesting. It can be seen as a positive signal for executive retention.
• Employees: May be seen as a standard compensation practice, potentially motivating other employees if similar programs exist.
• Management: Reinforces the alignment of executive interests with the company's long-term success.

Next Steps

• Darrin Uecker must remain in continuous service with Pulse Biosciences, Inc. through March 23, 2029, for the RSUs to vest.
• Upon vesting, Uecker will receive one share of Pulse Biosciences, Inc. common stock for each RSU.

Key Dates

Keywords

Pulse Biosciences, PLSE, Form 4, Restricted Stock Units, RSU, Stock Grant, Executive Compensation, Darrin Uecker, Chief Technology Officer, Beneficial Ownership, Vesting Schedule